Philip Comp, MD
Hematology & Oncology · Oklahoma City, OKNPI 1790754729
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 35 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$142
- AstraZeneca$122
- Incyte Corporation$112
- Genentech USA, Inc.$105
- Amarin Pharma, Inc.$76
- Scpharmaceuticals Inc.$67
- plus $467 from 17 others
What the payments were for
- Food & beverage$1,07198%
- Education$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 6 | $142 |
| AstraZeneca(2 entities) | 2 | $122 |
| Incyte Corporation | 2 | $112 |
| Genentech USA, Inc. | 1 | $105 |
| Amarin Pharma, Inc. | 1 | $76 |
| Scpharmaceuticals Inc. | 1 | $67 |
| Novo Nordisk | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Legend Biotech USA Inc. | 2 | $40 |
| Merck | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $19 |
| Syndax Pharmaceuticals, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| Geron Corporation | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,092 in reported general payments places this provider in the 25th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $16,198 |
| Hydroxyurea | 24 | $678 |
| Warfarin Sodium | 21 | $179 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.